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Background: The study evaluates the frequency of and indications for bone-metastases (BM)-related
surgery and/or radiotherapy in the palliative breast cancer (BC) situation and analyzes in which phase of
the palliative disease course surgery and/or radiotherapy was applied.
Methods: 340 patients who developed distant metastatic disease (DMD) and died (i.e. patients with
completed disease courses) were analyzed.
Results: From the entire study cohort, 237 patients (69.7%) were diagnosed with BM. Out of these,
116 patients (48.9%) received BM-related radiotherapy and/or surgery during the palliative situation.
Radiotherapy: 108 patients (45.6%) received 161 series (range: 1–5) with 217 volumina (range: 1–8) on
300 osseous sites. At 75.3% of the radiated sites, the spine was the most frequent radiated location.
Eighty-eight series (54.7%) were performed in the ﬁrst third of the metastatic disease survival (MDS)
period. The median survival after radiotherapy was 14 months (range: 0.2–121 months).
Surgery: In 37 patients (15.6%), 50 procedures (range: 1–4) were necessary to stabilize BM. The femur
predominated with 56.0% of the procedures. Twenty procedures (40.0%) were performed in the ﬁrst third
of survival follow-up. The median survival after surgery was 13.5 months (range: 0.5–49 months).
BC patients with BM had a signiﬁcantly improved MDS when radiotherapy and/or surgery for skeletal
metastases was embedded in the palliative approach (27.5 months vs. 19.5 months, po0.001). From the
118 patients who had a MDS of Z24 months, the majority (54.2%) had BM-related radiotherapy and/or
surgery during the palliative course.
Conclusions: Metastatic BC has become increasingly viewed as a chronic disease process. In a general
palliative therapy approach, which allows for treatment according to the principles of a chronic disease,
non-systemic therapy for BM, in particular radiotherapy, has a clearly established role in the therapy
concept.
& 2014 Elsevier GmbH. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
In many patients with distant metastatic breast cancer (BC), the
skeleton is the site of the most signiﬁcant tumor burden [1]. In
some cases, bone metastases (BM) are relatively silent but many
patients, particularly those who have less aggressively growing
tumors with a long-term course, develop clinically symptomatic
lesions which are not infrequently associated with severe pain.
In this situation, radiotherapy and/or surgery might be performed
with palliative intention and the primary goals of treatment
include prevention and palliation of symptoms, maintenance or
improvement of quality of life and prolongation of survival [2–4].
In the literature, there exists a large amount of information on
palliative radiotherapy and surgical interventions on BM during
the disease course of metastatic BC (overview in: [2,5–7]). How-
ever, most of the published studies evaluate only speciﬁc therapy
options in pre-selected groups of patients, e.g. most of the
published studies on palliative radiotherapy focused on the effect
of different fractionation regimens and total radiation doses [2]. In
doing so, these studies primarily reﬂect the perspective of one
oncological subdiscipline, namely radiation oncology or orthope-
dic surgery. However, they did not utilize control groups of
patients with metastases at the same site who were not radiated
Contents lists available at ScienceDirect
journal homepage: www.elsevier.com/locate/jbo
Journal of Bone Oncology
http://dx.doi.org/10.1016/j.jbo.2014.05.001
2212-1374/& 2014 Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
n Corresponding author at: Cantonal Hospital Winterthur, Department of
Gynecology & Obstetrics, Brauerstrasse 15, CH-8401 Winterthur, Switzerland.
Tel.: þ41 52 2662713; fax: þ41 52 2664512.
E-mail address: uwe.gueth@unibas.ch (U. Güth).
Journal of Bone Oncology 3 (2014) 54–60
or operated, nor take into account how these procedures were
embedded in the overall course of distant metastatic disease
(DMD).
In this study, we applied a more general approach along these
lines, which has previously been used only in few reports in the
literature [8]. Based on a prospective BC database including all
newly diagnosed BC cases at a large Swiss breast center over
a 20-year period, we aimed to give a comprehensive overview
regarding the frequency of BM and systematically evaluated how
the non-systemic BM-related therapy options radiotherapy and
surgery were actually clinically implemented in an unselected
cohort of patients with DMD. We use the term non-systemic
locoregional therapy to draw a clear distinction between radio-
therapy/surgery and systemic bone-targeted agents such as
bisphosphonates and denosumab. By doing so, we answer basic
questions such as “How many BC patients with BM can be
expected to receive BM-related radiotherapy and/or surgery dur-
ing their palliative disease courses, at which metastatic sites, at
what age, and in which phase of the disease course?”
2. Patients and methods
Data from the prospective relational Basel Breast Cancer
Database (BBCD), which includes all newly diagnosed primary
invasive BC cases treated at the University Women's Hospital
Basel, Switzerland since 1990, provided the basis for this study.
This institution comprises the largest breast center in the canton
of Basel and is representative of the population of the region. For
this study, data from all female patients who were diagnosed with
BC up to and including 2009 was analyzed (n¼1459).
During this 20-year period, 92 patients (6.3%) had DMD at
initial diagnosis, or in other words, had primary metastatic disease
(PMD). In 2011, with the exception of 37 patients (2.5% of the
entire study group) who were lost to follow-up after a median
follow-up time of 36 months (range 1–166 months), outcome
information was available for all patients recorded in the BBCD. As
of March 2011, 277 patients (20.3% of all patients who had stages
I–III disease at initial BC diagnosis) had developed distant metas-
tases over time, in other words, had secondary metastatic disease
(SMD). The median time between initial BC diagnosis and ﬁrst
diagnosis of DMD was 38.5 months (range: 2–215 months).
Out of 369 patients with conﬁrmed distant metastatic BC, we
were able to obtain information regarding the time of diagnosis of
metastatic disease and date of death but we did not have complete
information about the disease course and palliative therapy details
for six patients (PMD, n¼1; SMD, n¼5). Thus, these patients were
not considered for analysis, and ultimately 363 patients were
included in the study.
The patients in this cohort were followed until death. Patients
who remained alive were followed until 2013, thus all surviving
patients had a follow-up time of at least 24 months. The outcome
status of the cohort (n¼363) was as follows: (1) died of metastatic
BC: 316 patients (87.1%); (2) died of other causes: 24 patients
(6.6%); (3) alive with metastatic disease: 20 patients (5.5%); and
(4) alive, no evidence of disease: 3 patients (0.8%).
In order to analyze patterns of distant metastatic disease and to
examine metastatic BM-related radiation oncology and surgical
procedures during the palliative therapy course, we examined only
the 340 patients who ultimately died of their metastatic disease
(PMD, n¼78; SMD, n¼262). In other words, we analyzed only
completed disease and treatment courses.
2.1. Bone metastases within metastatic patterns
We evaluated six metastatic sites: (1) bone, (2) liver, (3) lung,
(4) brain, (5) lymph nodes (not including ipsilateral BC-related
locoregional lymph nodes), and (6) other anatomical sites.
For each case, the location of the metastatic lesions and the
number of metastatic sites were recorded. In all cases, this
constellation was described at the initial diagnosis of DMD (ﬁrst
DMD event). When additional metastatic lesions subsequently
developed at other locations, the new metastatic site was
described as the “second DMD event”. As an example, a patient
was diagnosed with DMD, consisting of bone and liver metastases,
in June 2005. This was recorded as two metastatic sites at the “ﬁrst
DMD event”. Palliative therapy was initiated. In August 2007, the
disease progressed and additional lung metastases were found.
This was recorded as one site for the “second DMD event”. In this
particular case, we recorded two DMD events, a total of three
metastatic sites and a time of 13 months between the ﬁrst and
second DMD event. When metastatic lesions developed in differ-
ent locations or regions within an organ or organ system (e.g.
isolated BM of the spine at the ﬁrst diagnosis of DMD and several
months later additional femoral metastases), these were not
considered as separate DMD events.
Usually, the lesions of the ﬁrst and second DMD events reliably
reﬂect the course of DMD and determine the disease course and
palliative therapy administered (in only two cases, there was a
clinically relevant metastatic site at a third DMD event: in both
cases, the patients developed brain metastases). Additional devel-
opment of metastatic lesions might occur in some late palliative
stages but since palliative care and diagnostic work-up in this
situation vary considerably depending on the individual situation,
the recording of a third DMD event would not be expected to
provide clinically meaningful information. Table 1 lists the dis-
tribution of metastatic locations of the study cohort.
Table 1
Patterns of distant metastatic sites in 340 patients.
Metastatic sites DMD event 1 DMD event 2 All DMD eventsa
Patients, n¼340 (%) Patients, n¼164 (%) Patients, n¼340 (%)
Metastatic sites, n¼570 Metastatic sites, n¼210 Metastatic sites, n¼782
Bone 209 (61.5) 28 (17.1) 237 (69.7)
Lung 128 (37.6) 47 (28.7) 175 (51.5)
Liver 89 (26.2) 60 (36.6) 149 (43.8)
Brain 24 (7.1) 38 (23.2) 64 (18.8)1
Lymph nodes (excluding ipsi-lateral locoregional LNs) 85 (25.0) 12 (7.3) 97 (28.5)
Other locations 35 (10.3) 25 (15.2) 60 (17.6)
One metastatic site at diagnosis of DMD 188 (55.2)
One metastatic site at diagnosis of DMD: bone metastases only 96 (28.2)
DMD: distant metastatic disease; LN: lymph node.
a Additionally included: two patients with brain metastases at a third DMD event.
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2.2. Exclusion criterion: intervention on the primary breast tumor at
the time of diagnosis (stage IV, primary metastatic BC)
From all women who were diagnosed with PMD (n¼91), 43
patients (47.3%) had removal of the primary breast tumor at ﬁrst
diagnosis of DMD. This subgroup represents a particular group of
patients who had surgery during their palliative disease course,
because surgery in these patients was always performed at the
beginning of the DMD. In the cases where the primary breast
tumor was removed at the time of diagnosis, these operations
were not included in the “surgery analysis”. Accordingly, post-
operative radiation following the resection of the primary lesion
(n¼8) was not included in the “radiotherapy analysis”.
2.3. Surgery analysis
In the cases presented in our study, there were no surgical
procedures for diagnostic purposes only. In all cases where
metastases were removed, surgery had been performed to alle-
viate metastasis-related symptoms. Diagnostic procedures, even if
they had an invasive character (e.g. radiologically guided needle
biopsy) were not considered as surgical interventions.
2.4. Radiotherapy analysis: deﬁnition of series, volumina and
anatomic sites
For each case, the number of radiotherapeutic interventions
(series), their irradiated planning target volumes (PTV) and the
corresponding osseous metastatic sites were recorded. For exam-
ple, a patient received radiotherapy for BM in June 2005. In this
ﬁrst treatment series, two PTV were irradiated: the humerus with
15 Gy and a section of the thoracic and lumbar spine (T4-L1) with
30 Gy. In a second series in January 2006, the brain (30 Gy) and
two further bone volumes – right femur (24 Gy) and a segment of
the cervical and thoracic spine (C3-T1, 30 Gy) – were irradiated. In
this particular case, we recorded two radiotherapy series, ﬁve PTV
and a total of seven anatomic sites (brain, humerus, femur, cervical
vertebrae, lumbar vertebrae, and 2 thoracic vertebrae).
2.5. How were radiotherapy and surgical interventions for bone
metastases embedded in the palliative setting?
For each intervention, we recorded the time to procedure, in
months, with respect to the ﬁrst diagnosis of DMD and the survival
time after the procedure. Based on this data, we also calculated in
which third of the palliative disease course the procedure had
been performed. For example, a patient was diagnosed with DMD,
consisting of bone and liver metastases, in June 2005. Eight
months later, she received surgery for BM. Eventually, the patient
died of metastatic BC in June 2008 (i.e. 28 months after surgery
and 36 months after the ﬁrst diagnosis of DMD). In this particular
case, we recorded that the surgical procedure had been performed
in the ﬁrst third of the palliative disease course.
2.6. Institutional review board
The study design and data collection methods were approved
by our institutional review board.
2.7. Statistical analysis
Since the ages of all subsets were found to have almost a
Gaussian distribution, statistical differences between ages of the
subsets were analyzed using the unpaired t-test. The therapeutic
approaches and the survival times after the interventions were
compared by means of the nonparametric Wilcoxon-Test. Compar-
isons between nominal parameters were made with the Fisher
exact test. In all statistical tests the level of signiﬁcance was
po0.05. Statistical evaluations were performed with Splus soft-
ware (Version 6.1, Insightful Corporation, Seattle, WA, USA).
3. Results
In our study cohort of 340 patients, 237 patients (69.7% of all
patients with completed DMD courses; Table 1) were diagnosed
with BM. Table 1 shows the distribution of the metastatic sites. BMs
were the most frequent metastatic location, followed by metastases
of the lung (51.5%), liver (43.8%), lymph nodes (28.5%) and brain
(18.8%).
3.1. Bone metastases vs. distant metastases other than
bone metastases
The patients who developed BM during the palliative situation
were signiﬁcantly younger compared to patients who developed
visceral metastases only (median age: 63 years [range: 28–91] vs.
68 years [range: 30–94], po0.001).
Compared to patients who had visceral metastases at ﬁrst
diagnosis of DMD (n¼244), patients who had BM as the only
metastatic site at ﬁrst diagnosis of DMD (n¼96) had a signiﬁcantly
improved metastatic disease survival (MDS; median: 27.5 months
[range: 1–135] vs. 17 months [range: 0.5–123], po0.001).
3.2. Radiotherapy and/or surgery for bone metastases
Out of 237 patients who had BM, 116 patients (48.9%) received
bone-related radiotherapy and/or surgery during the palliative
situation.
Table 2
Metastatic sites and palliative radiotherapy and surgery.
Metastatic sites All DMD events Number of patients who had
DMD-related radiotherapy
(% of the DMD site occurrence)
Number of patients who had
DMD-related surgery
(% of the DMD site occurrence)
Patients, n¼340 (%)
DMD sites, n¼782
Bone 237 (69.7) 108 (45.6) 37 (15.6)
Lung 175 (51.5) 1 (0.6) 1 (0.6)
Liver 149 (43.8) 1 (0.7) 1 (0.7)
Brain 64 (18.8) 55 (85.9) 4 (5.4)
Lymph nodes (excluding ipsi-lateral locoregional LNs) 97 (28.5) 8 (8.2) 1 (1.0)
Other locations 60 (17.6) 9 (15.0) 10 (16.7)
Local recurrence (breast and/or ipsilateral locoregional LNs)a 66 (19.4) 22 (33.3) 13 (19.7)
DMD: distant metastatic disease; LN: lymph node.
a Only cases with local recurrences which were diagnosed and had radiotherapy and/or surgery after the diagnosis of other distant metastases.
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– One hundred and eight patients (45.6%) received 161 series
(range: 1–5) with 217 volumina (range: 1–8) of palliative
radiotherapy on 300 osseous sites (Table 2). At 75.3% of the
radiated sites, the spine was the most frequent radiated loca-
tion; the second most common location was with 9.6% the
femur (Table 3).
– In 37 patients (15.6%), 50 surgical procedures (range: 1–4) were
necessary to stabilize osseous structures due to metastatic
involvement (Table 2). The femur predominated with 56.0% of
the procedures, followed by the spine with 28.0% (Table 3).
– In 29 patients (12.2%), both therapy options, radiotherapy and
surgery, were applied.
3.3. The metastatically involved bone as radiotherapeutic and/or
surgical therapy target in the context of palliative therapy
– Radiotherapy: among the 159 BC patients who received pallia-
tive radiotherapy (46.8% of the entire cohort of 340 patients),
a total of 249 series with 329 PTV were applied (Table 4).
The most common sites for radiotherapy were the bone (217
volumes, 65.9% of all radiated volumes) and the brain (57
volumes, 17.3%). Patients who had radiotherapy for BM had
a median age at the time of procedure of 58 years (mean
age: 60.5 years, range: 37–89 years). In comparison, patients
who had radiotherapy for brain metastases were signiﬁcantly
younger (mean: 55.4 years, p¼0.021).
– Surgery: among the 57 BC patients who were surgically treated
in the palliative situation (16.8% of the entire cohort of patients
with DMD), a total of 83 procedures were performed (Table 5).
The most common sites for palliative surgery were the bone
(60.2%) and the breast/locoregional lymph node sites (19.2%).
– Radiotherapy: eighty-eight out of 161 radiotherapy series
(54.7%) for BM were performed in the ﬁrst third of the survival
period (i.e. period of MDS); approximately 30% of the proce-
dures were performed in the last third (n¼47; Table 6).
The median survival after radiotherapy was 14 months (range:
0.2–121 months) (Table 6).
– Surgery: twenty out of 50 procedures for BM (40.0%) were
performed in the ﬁrst third of survival follow-up and 15 opera-
tions (30.0%) during each of the last two-thirds (Table 6). The
median survival after surgery was 13.5 months (range: 0.5–49
months) (Table 6).
3.4. Pathological fractures
In 35 patients (14.8% of the patients who had BM), a total of
42 pathologic fractures occurred (32 patients had one event, two
patients had two events, and a further two patients developed
four fractures). Of the patients who suffered pathological fractures,
in 12 cases (34.3%) BM was ﬁrst diagnosed by this event. Only
Table 3
Palliative locoregional bone therapy.
A. Radiotherapy: 108 patients received 161 series with 217 volumina on 300
osseous sites.
B. Surgery: 37 patients received 50 surgical procedures.
Osseous sites A. Radiotherapy B. Surgery
Complete number
of sites, n¼300 (%)
Complete number
of sites, n¼50 (%)
Vertebral column, including pelvis 226 (75.3) 14 (28.0)
Cervical vertebrae 31 (10.3) 3 (6.0)
Thoracic vertebrae 77 (25.7) 5 (10.0)
Lumbar vertebrae 65 (21.7) 3 (6.0)
Pelvis incl. sacrum and coccyx 53 (17.6) 3 (6.0)
Bony thorax 23 (7.7) 1 (2.0)
Ribs 12 (4.0) –
Sternum 11 (3.7) –
Clavicle – 1 (2.0)
Femur 29 (9.6) 28 (56.0)
Tibia/ﬁbula/foot 5 (1.7) –
Humerus 12 (4.0) 6 (12.0)
Skull 5 (1.7) 1 (2.0)
Table 4
Disease-related radiotherapy in breast cancer patients with distant metastatic
disease.
Study cohort 340
A. Breast cancer-related radiotherapy 159 (46.8)
B. No radiotherapy 181 (53.2)
Breast cancer-related radiotherapy
Number of patients 159
Number of series 249
Median/mean (range) 1/1.6 (1–5)
Number of planning target volumes 329
Median/mean (range) 2/2.0 (1–8)
Metastatic sites/radiation volumes 329 (100)
Bone 217 (65.9)
Vertebrae and osseous pelvis 137 (41.6)
Other sites 80 (24.3)
Brain 57 (17.3)
Other locations 28 (8.5)
Skin/soft tissue 13 (3.8)
Mediastinum 6 (1.8)
Eye 3 (0.9)
Lung 3 (0.9)
Cervical lymph nodes 2 (0.6)
Liver 1 (0.3)
Breast and locoregional lymph nodes 27 (8.2)
Progression of the primary breast tumor, no surgery 3 (0.9)
Recurrence at the chest wall, no surgery 6 (1.8)
Chest wall after surgery for local recurrence 1 (0.3)
Recurrence at locoregional lymph nodes 17 (5.2)
Table 5
Disease-related surgery in breast cancer patients with distant metastatic disease.
Study cohort 340
A. Breast cancer-related surgery 57 (16.8)
B. No surgery 283 (83.2)
Breast cancer-related surgery
Number of patients 57
Number of procedures/sites 83 (100)
Bone 50 (60.2)
Femur 28 (33.7)
Vertebrae 14 (16.9)
Humerus 6 (7.2)
Clavicle 1 (1.2)
Jawbone 1 (1.2)
Lung 1 (1.2)
Liver 1 (1.2)
Brain 4 (4.8)
Other locations 11 (13.4)
Ovary/peritoneal cavity 5 (6.0)
Skin (excluding breast region) 3 (3.6)
Lymph nodes (mediastinal) 1 (1.2)
Urinary bladder 1 (1.2)
Gallbladder 1 (1.2)
Breast/locoregional recurrence 16 (19.2)
Metastasectomy after mastectomy 8 (9.6)
Mastectomy after breast-conserving therapy 4 (4.8)
Tumorectomy after breast-conserving therapy 1 (1.2)
Locoregional lymph nodes 3 (3.6)
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in three cases, a pathological fracture occurred at a previously
radiated bone region.
In 32 of the 42 events (76.2%), the patients underwent surgery;
in four cases (9.5%), the patients received radiotherapy for pain
relief and for prevention of further fractures. In six cases (14.3%),
the fractures were neither stabilized by surgery, nor did the
patients receive radiotherapy. Table 7.
3.5. Patients with bone metastases: comparison between patients
who had radiotherapy and those who had surgery
In the comparison between both groups, the patients who had
radiotherapy were signiﬁcantly younger (58 years vs. 64 years,
po0.001). There was a trend that radiotherapeutic interventions
were performed at an earlier stage of the metastatic disease course
(ﬁrst third of DMD: 54.7% vs. 40.0%, p¼0.077). The median survival
after the procedures was similar (radiotherapy: 14 months vs.
surgery: 13.5 months, p¼0.921).
3.6. Patients with bone metastases: comparison between patients
who had radiotherapy and/or surgery vs. patients who had not
Patients who were treated with radiotherapeutic and/or surgi-
cal interventions were signiﬁcantly younger when compared with
those who had neither radiotherapy nor surgery (65 years vs. 61
years, p¼0.025).
With regard to systemic therapy options, there were no signiﬁ-
cant differences between both groups (no systemic therapy: 9.5%
vs. 14.0%, p¼0.318; chemotherapy: 68.1% vs. 57.9%, p¼0.109;
endocrine therapy: 67.2% vs. 67.9%, p¼1.00). In cases where
palliative systemic therapy was applied, the median number of
therapy lines was higher in the group of patients who received
radiotherapy and/or surgery (3 vs. 2, po0.001).
BC patients with BM had a signiﬁcantly improved MDS when
radiotherapy and/or surgery for skeletal metastases was embedded
in the palliative approach (27.5 months vs. 19.5 months, po0.001).
When one compares both groups with regard to a MDS of Z24
months, a higher percentage of patients who had radiation and/or
surgery during the palliative disease course reached this mark
compared to patients who had no such interventions (54.7% vs.
43.9%, p¼0.121). From the 118 patients who had a MDS of Z24
months, the majority (54.2%) had BM-related radiotherapy and/or
surgery during the palliative course.
4. Discussion
When interpreting our results, the following strength and
limitations of the study must be considered. Firstly, our study
comes from a single region of a small country with a high
socioeconomic status. Secondly, our study analyzed retrospective
data. Furthermore, it must be considered that the data on radio-
therapy reported in this study might reﬂect a certain attitude
towards palliative radiotherapy at our institution and the regio-
nal referral practice to our radiooncological therapy unit. In the
palliative BC setting, there is currently no standard of care for this
heterogeneous group of patients, and treatment decisions are
made on an individual basis. In this scenario, it is easy to imagine
that particular regional or even site-speciﬁc attitudes towards
palliative therapy options might inﬂuence therapy decisions
considerably more than in the adjuvant situation with its more
clearly deﬁned and widely accepted therapy guidelines. Thus, the
rates of radiotherapeutic procedures reported in this study might
vary from those of other cohorts of metastatic BC patients treated
elsewhere. We think that institution-speciﬁc differences are
negligible for our data on orthopedic surgery. In most of the
cases, these are emergency procedures for patients with patho-
logic fractures and surgery is inevitable and not debatable in
most cases.
On the other hand, there it is a particular strength to our study:
the complete documentation of the study cohort.
– The basic cohort recorded in a prospective database included
all patients newly diagnosed with BC over a 20-year period
(1990–2009). With a very low lost-to-follow-up rate of o3%,
only very few patients, who could have potentially developed
DMD, were missed. Furthermore, we made great efforts to also
include patients who are usually underrepresented in large BC
databases and thus are underreported in the oncologic litera-
ture, namely those who did not have any treatment from
specialized oncologists, and did not receive surgery, radio-
therapy and/or antineoplastic therapy.
– The vast majority (498%) of the palliative courses were
completely documented with regard to metastatic patterns
and palliative therapy.
Table 6
Radiotherapy and surgery for bone metastases: patient's age at procedure, time of
procedure within the disease course of metastatic breast cancer and survival after
procedure during the palliative situation.
Metastatic
sites:
A. Radiotherapy B. Surgery
I. All procedures
n¼249 series
(%)
II. Bone
procedures
n¼161 series (%)
I. All
procedures
n¼83 (%)
II. Bone
procedures
n¼50 (%)
Age (years)
Mean/
median
60.6/60 60.5/58 61.0/61.5 63.7/64
(range) (32–89) (37–89) (29–89) (39–89)
Phase of DMD
First
third
121 (48.6) 88 (54.7) 34 (41.0) 20 (40.0)
Second
third
44 (17.7) 26 (16.1) 25 (30.1) 15 (30.0)
Last
third
84 (33.7) 47 (29.2) 24 (28.9) 15 (30.0)
Series performed during:
last 12
months
of life
135 (54.2) 78 (48.4) 35 (42.1) 24 (48.0)
last 6
months
of life
95 (38.2) 53 (32.9) 26 (31.3) 18 (36.0)
Survival after radiotherapy (months)
Mean/
median
17.4/10 18.9/14 18.3/16 16.7/13.5
(range) (0.2–123) (0.2–121) (0.5–89) (0.5–49)
DMD: distant metastatic disease.
Table 7
Palliative systemic therapy in 237 BC patients with bone metastases.
No radiotherapy or
surgery (n¼121)
Radiotherapy and/or
surgery (n¼116)
No systemic therapy 17 (14.0) 11 (9.5)
Chemotherapy (CT) only 22 (18.2) 27 (23.3)
Endocrine therapy (ET) only 34 (28.1) 26 (22.4)
CTþET 48 (39.7) 52 (44.8)
Median number of systemic
therapy lines (range)
2 (1–8) 3 (1–10)
Use of bone-targeted agents 90 (74.4) 80 (70.0)
CT: chemotherapy; ET: endocrine therapy.
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This valuable feature of complete documentation of BC disease
courses is essential to reach our study goals, namely to give
a comprehensive overview regarding the incidence of BM and
to give a detailed description regarding metastases-related non-
systemic locoregional therapy. Most studies regarding locoregional
therapy of BM evaluated certain orthopedic interventions or
feasibility of different radiation schedules and reported their
respective outcome data [2,5–7]. In doing so, these studies
primarily reﬂect the perspective of one oncological subdiscipline,
namely orthopedic surgery or radiation oncology. However, they
did not utilize control groups of patients with BM who were not
radiated or did not receive surgery (in some cases, they included
“non-therapy”-control groups which were mostly more or less
arbitrarily selected subgroups). Furthermore, these studies usually
do not take into account the overall course of DMD. Thus, they
failed to answer basic questions such as “How many BC patients
with BM can be expected to have radiotherapy and/or surgery
during their palliative disease course?” or “How are these proce-
dures embedded in the entire disease and therapy course?”.
These questions require a general oncologic perspective and can
only be answered through examination of a complete cohort of
unselected patients with metastatic disease and by thorough
analysis of metastatic patterns [8]. In a recently published study,
Kuchuk et al. analyzed a comparable comprehensive approach;
however, the authors focused more on the use of systemic bone-
targeted agents [9].
In our study cohort comprised of 340 patients with distant
metastatic BC, a total of approximately 70% of the patients
developed BM during their palliative disease course (in compar-
ison, Kuchuk et al. found with an incidence of 73% similar results).
Approximately 62% of the patients had BM when DMD was
diagnosed (event 1); approximately half of them (or one fourth
of all patients with DMD) had BM as the only metastatic site.
Approximately 50% of the patients who developed BM during
their palliative disease course received BM-related radiotherapy
and/or surgery; 12% of the patients received both therapy options.
Our data conﬁrms that the majority of patients with BM will
respond to a low course of radiotherapy with good pain relief and
only a proportion of these patients will appear in the trauma
department with a pathological fracture requiring stabilization
[10]. Patients who received radiotherapy or surgery for BM had a
median survival after the procedures of 14 months. Patients with
BM who received radiotherapy and/or surgery had a signiﬁcantly
improved MDS compared to patients who had not (27.5 vs. 19.5
months).
Undoubtedly, through the introduction of a new generation of
effective agents with safer proﬁles in the last 20 years (e.g.,
endocrine therapy: third-generation aromatase inhibitors, fulves-
trant; chemotherapy: taxanes, capecitabine, liposomal doxorubi-
cin, gemcitabine, vinorelbine; immunotherapy: trastuzumab) and
of course, through considerable advances in supportive care,
longer survival times could be achieved. In our study cohort, the
median survival after palliative surgery for BM was 13.5 months;
this is considerably higher compared to a cohort of BC patients
who received surgical treatment for BM in Sweden during 1989
and 1994 in which the survival rate was 8 months [6]. Further-
more, bone-targeted agents such as bisphosphonates and deno-
sumab which have become a standard of care for patients with BM
lead to a signiﬁcant reduction in the incidence of, and time to
skeletal related events and bone pain [11–13]. These advances in
systemic palliative therapy increasingly allow the application of
chronic disease treatment concepts in metastatic BC (deﬁnition of
chronic disease and its therapy approach: long-lasting or recurrent
diseases which require a long period of treatment, supervision,
observation or care; they are caused by non-reversible pathologi-
cal alterations, leave residual disability, and can be altered but not
be cured by various therapies [14,15]; both chronic non-malignant
diseases and longer metastatic disease courses require periodic
therapy to control progressive course, and symptoms can be
treated using strategies that permit stabilization with treatment
regimens that have limited cumulative toxicity). One cannot assess
exactly the impact of non-systemic locoregional procedures for BM
on increased survival rates in metastatic BC. In our study, we have
deliberately foregone drawing conclusions regarding the impact of
palliative radiotherapy and/or surgery on survival and reported
this data in a descriptive manner. In addition to the retrospective
approach of our study, there is a high degree of heterogeneity
within the entire cohort and the described particular subgroups,
which would make any analysis regarding palliative non-systemic
therapy for bone metastases and prognostic impact more than
debatable. On the other hand, it can be clearly stated that in the
cases in which palliative therapy results in longer survival times,
and thus the palliative therapy concepts resemble those of a
chronic disease, non-systemic locoregional therapy for BM, in
particular radiotherapy, is an established part of the overall
multimodal palliative therapy course. Radiotherapy is effective
even when the disease becomes refractory to systemic therapy
because ionizing radiation alters cell function in all viable cells
within the radiation ﬁeld. On the one hand, tumor shrinkage will
enable osteoblastic repair, on the other hand, the decrease of
osteoclast activity might be responsible for the success of radio-
therapy [16].
In order to further improve the overall care of patients with
BM, a multidisciplinary approach between oncologists on the one
hand and radiooncologists and orthopedic surgeons on the other
hand is required [10,17].
5. Conclusions
The vast majority of patients with DMD develop BM during
their palliative course. Nearly one half of the patients received
BM-related radiotherapy and/or surgery. In the last decade, meta-
static cancer has become increasingly viewed as a chronic disease
process. In a general palliative therapy approach, which allows the
treatment according to the principles of a chronic disease, non-
systemic locoregional therapy for BM, in particular radiotherapy, is
an integral part of the overall multimodal therapy concept.
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